Menu Search
Equities

Aroa Biosurgery Ltd

AROAF:PKC

Aroa Biosurgery Ltd

Actions
  • Price (USD)--
  • Today's Change--
  • Shares traded145.41k
  • 1 Year change--
  • Beta--
Data delayed at least 15 minutes, as of Sep 30 2024 13:05 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Aroa Biosurgery Limited is a soft-tissue regeneration company. It develops, manufactures, sells, distributes medical and surgical products to improve healing in complex wounds and soft tissue reconstruction. Its products are developed from the AROA extracellular matrix (ECM) technology platform, an extracellular matrix biomaterial derived from ovine forestomach. AROA ECM is an ECM biomaterial containing a rich and complex mix of biological molecules that is the building block for a range of soft tissue repair products. Its products include Endoform, Myriad Matrix, Myriad Morcells, Myriad Morcells Fine, Symphony and Reinforced Bioscaffolds. Endoform products support all phases of wound healing and are appropriate for use early in wound management to restore protease balance and advance healing to the proliferative phase. Myriad Matrix is an engineered ECM for soft tissue repair, reinforcement, and complex wounds.

  • Revenue in AUD (TTM)62.61m
  • Net income in AUD-9.63m
  • Incorporated2007
  • Employees261.00
  • Location
    Aroa Biosurgery Ltd64 Richard Pearse Drive, MangereAUCKLAND 2022New ZealandNZL
  • Phone+64 98693035
  • Websitehttps://aroa.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.